The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TRUMY | -15.14% | -12.35% | -2.6% | +283% |
| S&P | +19.89% | +109.18% | +15.89% | +722% |
Terumo Corp. engages in the manufacturing and sale of medical products and equipment. It operates through the following segments: Cardiac and Vascular Company, General Hospital Company, and Blood Management Company. The Cardiac and Vascular Company segment offers services and treatments including cardiac and vascular surgery and interventional therapies performed inside blood vessels. The General Hospital Company segment provides infusion and closed anticancer drug infusion systems, measuring devices system with communication functions, diabetes management, adhesion barrier, and peritoneal dialysis. The Blood Management Company segment offers a combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. The company was founded by Shibasaburo Kitasato on September 17, 1921 and is headquartered in Tokyo, Japan.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.80B | 8.6% |
| Gross Profit | $1.01B | 14.0% |
| Gross Margin | 55.96% | 2.7% |
| Market Cap | $27.07B | 11.4% |
| Market Cap / Employee | $0.88M | 0.0% |
| Employees | 30.7K | 0.3% |
| Net Income | $289.59M | 33.2% |
| EBITDA | $516.77M | 21.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.41B | 16.7% |
| Accounts Receivable | $1.26B | 9.5% |
| Inventory | 2.1K | 11.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $691.42M | -30.4% |
| Short Term Debt | $484.50M | 122.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 6.97% | 0.2% |
| Return On Invested Capital | 7.30% | -0.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $108.28M | -17.4% |
| Operating Free Cash Flow | $225.89M | -1.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 35.33 | 35.04 | 36.13 | 32.33 | 3.87% |
| Price to Book | 3.15 | 3.15 | 3.10 | 2.96 | 6.69% |
| Price to Sales | 4.27 | 4.32 | 4.06 | 3.90 | 2.96% |
| Price to Tangible Book Value | 5.58 | 5.40 | 5.37 | 4.92 | -1.26% |
| Price to Free Cash Flow TTM | 43.70 | 42.72 | 39.58 | 41.87 | -8.85% |
| Enterprise Value to EBITDA | 61.48 | 61.59 | 70.61 | 51.92 | -9.64% |
| Free Cash Flow Yield | 2.3% | 2.3% | 2.5% | 2.4% | 9.71% |
| Return on Equity | 9.0% | 9.4% | 8.6% | 9.2% | -0.26% |
| Total Debt | $1.22B | $1.21B | $1.43B | $1.18B | -2.89% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
